Compare ResMed Inc. (RMD) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while ABRDN Physical Gold Shares ETF trades at $41.7. The key difference: ResMed Inc. pays a 1.2% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals.
| RMD | SGOL | |
|---|---|---|
Market Cap | $31.73B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $283.28 | $51.41 |
52-Week Low | $182.82 | $34.68 |
Enterprise Value | $31.08B | — |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
SGOL is currently trading at $41.48, down 1.78% over the past 24 hours amid broader market volatility. The technical picture shows bearish momentum with moving averages signaling selling pressure, though oversold RSI conditions suggest potential for near-term stabilization. Recent news highlights strong institutional gold demand and positive analyst price targets despite current price weakness.
The outlook remains constructive with major banks forecasting gold price appreciation to $4,900-$5,600 by year-end, though near-term volatility persists due to Fed policy uncertainty and geopolitical tensions. Key risks include interest rate sensitivity and dollar strength, while institutional accumulation provides underlying support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
